Published in J Immunol on March 01, 2007
mTOR, metabolism, and the regulation of T-cell differentiation and function. Immunol Rev (2012) 1.74
PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta (2011) 1.60
Retracted A Role for PPARgamma in the Regulation of Cytokines in Immune Cells and Cancer. PPAR Res (2008) 1.48
PPAR gamma is highly expressed in F4/80(hi) adipose tissue macrophages and dampens adipose-tissue inflammation. Cell Immunol (2009) 1.43
Metabolic control of the Treg/Th17 axis. Immunol Rev (2013) 1.26
Regulation of Th17 differentiation by epidermal fatty acid-binding protein. J Immunol (2009) 1.11
The role of T cell PPAR gamma in mice with experimental inflammatory bowel disease. BMC Gastroenterol (2010) 1.10
Abscisic acid regulates inflammation via ligand-binding domain-independent activation of peroxisome proliferator-activated receptor gamma. J Biol Chem (2010) 1.10
Gamma-linolenic and stearidonic acids are required for basal immunity in Caenorhabditis elegans through their effects on p38 MAP kinase activity. PLoS Genet (2008) 1.09
Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care (2010) 1.07
Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPARgamma. J Nutr (2010) 1.07
Induced and natural regulatory T cells in the development of inflammatory bowel disease. Inflamm Bowel Dis (2013) 1.03
Abscisic acid ameliorates experimental IBD by downregulating cellular adhesion molecule expression and suppressing immune cell infiltration. Clin Nutr (2010) 1.02
Systems modeling of molecular mechanisms controlling cytokine-driven CD4+ T cell differentiation and phenotype plasticity. PLoS Comput Biol (2013) 1.01
The nuclear receptor PPARs as important regulators of T-cell functions and autoimmune diseases. Mol Cells (2012) 1.00
Model of colonic inflammation: immune modulatory mechanisms in inflammatory bowel disease. J Theor Biol (2010) 0.99
Immunoregulatory actions of epithelial cell PPAR gamma at the colonic mucosa of mice with experimental inflammatory bowel disease. PLoS One (2010) 0.99
PPARs Mediate Lipid Signaling in Inflammation and Cancer. PPAR Res (2008) 0.96
Nuclear control of the inflammatory response in mammals by peroxisome proliferator-activated receptors. PPAR Res (2013) 0.94
Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease. Mucosal Immunol (2010) 0.94
Predictive computational modeling of the mucosal immune responses during Helicobacter pylori infection. PLoS One (2013) 0.94
The cardinal role of the phospholipase A(2)/cyclooxygenase-2/prostaglandin E synthase/prostaglandin E(2) (PCPP) axis in inflammostasis. Inflamm Res (2011) 0.93
Modeling the role of peroxisome proliferator-activated receptor γ and microRNA-146 in mucosal immune responses to Clostridium difficile. PLoS One (2012) 0.93
Nutritional protective mechanisms against gut inflammation. J Nutr Biochem (2013) 0.92
Expert panel workshop consensus statement on the role of the environment in the development of autoimmune disease. Int J Mol Sci (2014) 0.91
PPARgamma regulates retinoic acid-mediated DC induction of Tregs. J Leukoc Biol (2009) 0.91
Peroxisome proliferator-activated receptor-γ agonists prevent in vivo remodeling of human artery induced by alloreactive T cells. Circulation (2011) 0.90
T cell PPARγ is required for the anti-inflammatory efficacy of abscisic acid against experimental IBD. J Nutr Biochem (2010) 0.89
ENteric Immunity SImulator: a tool for in silico study of gastroenteric infections. IEEE Trans Nanobioscience (2012) 0.87
Helicobacter pylori infection in a pig model is dominated by Th1 and cytotoxic CD8+ T cell responses. Infect Immun (2013) 0.87
PPARgamma as a potential therapeutic target in pulmonary hypertension. Ther Adv Respir Dis (2010) 0.87
PPAR-gamma: Therapeutic Potential for Multiple Sclerosis. PPAR Res (2008) 0.86
The role of peroxisome proliferator-activated receptor γ in immune responses to enteroaggregative Escherichia coli infection. PLoS One (2013) 0.86
Suppression of intestinal inflammation and inflammation-driven colon cancer in mice by dietary sphingomyelin: importance of peroxisome proliferator-activated receptor γ expression. J Nutr Biochem (2011) 0.85
Attenuation of islet-specific T cell responses is associated with C-peptide improvement in autoimmune type 2 diabetes patients. Clin Exp Immunol (2013) 0.84
PPARgamma Inhibitors as Novel Tubulin-Targeting Agents. PPAR Res (2008) 0.83
Peroxisome proliferator-activated receptor gamma is required for CD4+ T cell-mediated lymphopenia-associated autoimmunity. J Immunol (2011) 0.83
High beta-palmitate fat controls the intestinal inflammatory response and limits intestinal damage in mucin Muc2 deficient mice. PLoS One (2013) 0.82
Chemotherapeutic Properties of n-3 Polyunsaturated Fatty Acids - Old Concepts and New Insights. Immunol Endocr Metab Agents Med Chem (2009) 0.82
The role of nuclear receptors in regulation of Th17/Treg biology and its implications for diseases. Cell Mol Immunol (2015) 0.82
Cell mediators of autoimmune hepatitis and their therapeutic implications. Dig Dis Sci (2014) 0.82
Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and colorectal cancer. Gastroenterol Clin North Am (2010) 0.81
PPARγ negatively regulates T cell activation to prevent follicular helper T cells and germinal center formation. PLoS One (2014) 0.80
PPARγ Agonists in Adaptive Immunity: What Do Immune Disorders and Their Models Have to Tell Us? PPAR Res (2013) 0.80
Atheroprotective effects of conjugated linoleic acid. Br J Clin Pharmacol (2016) 0.79
Dietary n-3 PUFA Protects Mice from Con A Induced Liver Injury by Modulating Regulatory T Cells and PPAR-γ Expression. PLoS One (2015) 0.78
Gender-specific differences in PPARγ regulation of follicular helper T cell responses with estrogen. Sci Rep (2016) 0.77
Deletion of PPAR-γ in immune cells enhances susceptibility to antiglomerular basement membrane disease. J Inflamm Res (2010) 0.76
Ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, inhibits proliferation and differentiation of th17 cells. Biomol Ther (Seoul) (2015) 0.76
Gastrointestinal Cytoprotection by PPARγ Ligands. PPAR Res (2010) 0.76
Peroxisome proliferator-activated receptor-γ is downregulated in ulcerative colitis and is involved in experimental colitis-associated neoplasia. Oncol Lett (2015) 0.75
Madecassic acid, the contributor to the anti-colitis effect of madecassoside, enhances the shift of Th17 toward Treg cells via the PPARγ/AMPK/ACC1 pathway. Cell Death Dis (2017) 0.75
Peroxisome proliferator-activated receptor γ deficiency in T cells accelerates chronic rejection by influencing the differentiation of CD4+ T cells and alternatively activated macrophages. PLoS One (2014) 0.75
PKC/NADPH oxidase are involved in the protective effect of pioglitazone in high homocysteine-induced paracrine dyfunction in endothelial progenitor cells. Am J Transl Res (2017) 0.75
Loss of Peripheral Tolerance in Emphysema. Phenotypes, Exacerbations, and Disease Progression. Ann Am Thorac Soc (2015) 0.75
Induction of Colonic Regulatory T Cells by Mesalamine by Activating the Aryl Hydrocarbon Receptor. Cell Mol Gastroenterol Hepatol (2017) 0.75
Sex-Based Selectivity of PPARγ Regulation in Th1, Th2, and Th17 Differentiation. Int J Mol Sci (2016) 0.75
Therapeutic Treatment of Arthritic Mice with 15-Deoxy Δ(12,14)-Prostaglandin J2 (15d-PGJ2) Ameliorates Disease through the Suppression of Th17 Cells and the Induction of CD4(+)CD25(-)FOXP3(+) Cells. Mediators Inflamm (2016) 0.75
Sex-specific regulation of immune responses by PPARs. Exp Mol Med (2017) 0.75
The human-bacterial pathogen protein interaction networks of Bacillus anthracis, Francisella tularensis, and Yersinia pestis. PLoS One (2010) 1.38
Dietary abscisic acid ameliorates glucose tolerance and obesity-related inflammation in db/db mice fed high-fat diets. Clin Nutr (2006) 1.26
Immune-mediated mechanisms potentially regulate the disease time-course of duchenne muscular dystrophy and provide targets for therapeutic intervention. PM R (2009) 1.22
Genistein induces pancreatic beta-cell proliferation through activation of multiple signaling pathways and prevents insulin-deficient diabetes in mice. Endocrinology (2010) 1.17
Loss of PPAR gamma in immune cells impairs the ability of abscisic acid to improve insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression and macrophage infiltration into white adipose tissue. J Nutr Biochem (2007) 1.13
The role of T cell PPAR gamma in mice with experimental inflammatory bowel disease. BMC Gastroenterol (2010) 1.10
Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPARgamma. J Nutr (2010) 1.07
Immunomodulatory properties of conjugated linoleic acid. Am J Clin Nutr (2004) 1.07
Activation of PPAR gamma and alpha by punicic acid ameliorates glucose tolerance and suppresses obesity-related inflammation. J Am Coll Nutr (2009) 1.03
Nutritional regulation of porcine bacterial-induced colitis by conjugated linoleic acid. J Nutr (2002) 1.03
Dysregulated intracellular signaling and inflammatory gene expression during initial disease onset in Duchenne muscular dystrophy. Am J Phys Med Rehabil (2009) 1.02
Abscisic acid ameliorates experimental IBD by downregulating cellular adhesion molecule expression and suppressing immune cell infiltration. Clin Nutr (2010) 1.02
Systems modeling of molecular mechanisms controlling cytokine-driven CD4+ T cell differentiation and phenotype plasticity. PLoS Comput Biol (2013) 1.01
Abscisic acid synergizes with rosiglitazone to improve glucose tolerance and down-modulate macrophage accumulation in adipose tissue: possible action of the cAMP/PKA/PPAR γ axis. Clin Nutr (2010) 1.01
Model of colonic inflammation: immune modulatory mechanisms in inflammatory bowel disease. J Theor Biol (2010) 0.99
Immunoregulatory actions of epithelial cell PPAR gamma at the colonic mucosa of mice with experimental inflammatory bowel disease. PLoS One (2010) 0.99
Abscisic acid ameliorates atherosclerosis by suppressing macrophage and CD4+ T cell recruitment into the aortic wall. J Nutr Biochem (2010) 0.99
Green tea extract decreases muscle pathology and NF-kappaB immunostaining in regenerating muscle fibers of mdx mice. Clin Nutr (2009) 0.99
Zinc deficiency alters host response and pathogen virulence in a mouse model of enteroaggregative Escherichia coli-induced diarrhea. Gut Microbes (2014) 0.96
Computational modeling-based discovery of novel classes of anti-inflammatory drugs that target lanthionine synthetase C-like protein 2. PLoS One (2012) 0.95
Pomegranate seed oil, a rich source of punicic acid, prevents diet-induced obesity and insulin resistance in mice. Food Chem Toxicol (2011) 0.95
Predictive computational modeling of the mucosal immune responses during Helicobacter pylori infection. PLoS One (2013) 0.94
Gene regulatory network reveals oxidative stress as the underlying molecular mechanism of type 2 diabetes and hypertension. BMC Med Genomics (2010) 0.93
Modeling the role of peroxisome proliferator-activated receptor γ and microRNA-146 in mucosal immune responses to Clostridium difficile. PLoS One (2012) 0.93
Enteroaggregative Escherichia coli strain in a novel weaned mouse model: exacerbation by malnutrition, biofilm as a virulence factor and treatment by nitazoxanide. J Med Microbiol (2013) 0.92
Nutritional protective mechanisms against gut inflammation. J Nutr Biochem (2013) 0.92
Systemic effects of white adipose tissue dysregulation and obesity-related inflammation. Obesity (Silver Spring) (2010) 0.89
T cell PPARγ is required for the anti-inflammatory efficacy of abscisic acid against experimental IBD. J Nutr Biochem (2010) 0.89
Molecular modeling of lanthionine synthetase component C-like protein 2: a potential target for the discovery of novel type 2 diabetes prophylactics and therapeutics. J Mol Model (2010) 0.89
Pomegranate seed oil reduces intestinal damage in a rat model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol (2012) 0.88
Virtual Screening as a Technique for PPAR Modulator Discovery. PPAR Res (2009) 0.88
Preventive and prophylactic mechanisms of action of pomegranate bioactive constituents. Evid Based Complement Alternat Med (2013) 0.88
ENteric Immunity SImulator: a tool for in silico study of gastroenteric infections. IEEE Trans Nanobioscience (2012) 0.87
Helicobacter pylori infection in a pig model is dominated by Th1 and cytotoxic CD8+ T cell responses. Infect Immun (2013) 0.87
The role of peroxisome proliferator-activated receptor γ in immune responses to enteroaggregative Escherichia coli infection. PLoS One (2013) 0.86
Emerging significance of NLRs in inflammatory bowel disease. Inflamm Bowel Dis (2014) 0.86
Suppression of intestinal inflammation and inflammation-driven colon cancer in mice by dietary sphingomyelin: importance of peroxisome proliferator-activated receptor γ expression. J Nutr Biochem (2011) 0.85
Peroxisome proliferator-activated receptors: bridging metabolic syndrome with molecular nutrition. Clin Nutr (2006) 0.85
Putting the pieces of the puzzle together - a series of hypotheses on the etiology and pathogenesis of type 1 diabetes. Med Hypotheses (2006) 0.85
Catalpic acid decreases abdominal fat deposition, improves glucose homeostasis and upregulates PPAR alpha expression in adipose tissue. Clin Nutr (2008) 0.84
CD4+ T-cell responses and distribution at the colonic mucosa during Brachyspira hyodysenteriae-induced colitis in pigs. Immunology (2005) 0.83
Genetics and molecular specificity of sialylation of Histophilus somni lipooligosaccharide (LOS) and the effect of LOS sialylation on Toll-like receptor-4 signaling. Vet Microbiol (2011) 0.82
Modulation of hepatic PPAR expression during Ft LVS LPS-induced protection from Francisella tularensis LVS infection. BMC Infect Dis (2010) 0.82
Multiscale modeling of mucosal immune responses. BMC Bioinformatics (2015) 0.82
Dietary α-eleostearic acid ameliorates experimental inflammatory bowel disease in mice by activating peroxisome proliferator-activated receptor-γ. PLoS One (2011) 0.82
Dietary abscisic acid ameliorates influenza-virus-associated disease and pulmonary immunopathology through a PPARγ-dependent mechanism. J Nutr Biochem (2012) 0.82
Mutations to essential orphan response regulator HP1043 of Helicobacter pylori result in growth-stage regulatory defects. Infect Immun (2013) 0.82
Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy? Inflamm Bowel Dis (2014) 0.81
Dietary modulation of inflammation-induced colorectal cancer through PPARγ. PPAR Res (2009) 0.80
Differential requirements for proliferation of CD4+ and gammadelta+ T cells to spirochetal antigens. Cell Immunol (2003) 0.79
Early evidence of increased risk for metabolic syndrome in young men with latent obstructive sleep apnea. Metab Syndr Relat Disord (2010) 0.79
Animal models of enteroaggregative Escherichia coli infection. Gut Microbes (2013) 0.78
Dietary modulators of peroxisome proliferator-activated receptors: implications for the prevention and treatment of metabolic syndrome. J Nutrigenet Nutrigenomics (2008) 0.78
Expression of PPAR γ in intestinal epithelial cells is dispensable for the prevention of colitis by dietary abscisic acid. ESPEN J (2012) 0.77
Deletion of PPAR-γ in immune cells enhances susceptibility to antiglomerular basement membrane disease. J Inflamm Res (2010) 0.76
Pharmacophore modeling improves virtual screening for novel peroxisome proliferator-activated receptor-gamma ligands. J Comput Aided Mol Des (2015) 0.76
Translational research and efficacy of biologics in Crohn's disease: a cautionary tale. Expert Rev Clin Immunol (2014) 0.76
ENISI SDE: A New Web-Based Tool for Modeling Stochastic Processes. IEEE/ACM Trans Comput Biol Bioinform (2015) 0.76
Response to letter to the editor - implementation of integrative approaches to improve the design of Crohn's disease clinical trials. Clin Nutr (2012) 0.75
Translating nutritional immunology into drug development for inflammatory bowel disease. Curr Opin Gastroenterol (2016) 0.75